Skip to main content
Top
Published in: Pediatric Cardiology 5/2010

01-07-2010 | Original Article

Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension

Authors: Robyn J. Barst, Gabriella Agnoletti, Alain Fraisse, James Baldassarre, David L. Wessel, For the NO Diagnostic Study Group

Published in: Pediatric Cardiology | Issue 5/2010

Login to get access

Abstract

The objective of this study was to determine whether a combination of inhaled nitric oxide (iNO) and O2 is more effective than 100% O2 or iNO alone for acute vasodilator testing in children. An open, prospective, randomized, controlled trial was conducted at 16 centers. Subjects were children 4 weeks to 18 years of age with pulmonary hypertension (PH) and increased pulmonary vascular resistance (PVR) undergoing right heart catheterization for acute vasodilator testing. All patients were tested with each of three agents (80 ppm iNO, 100% O2, combination of 80 ppm iNO/100% O2) in three 10-min treatment periods, and hemodynamic measurements obtained. Primary outcome measures were percentages of acute responders with O2 alone vs. iNO/O2 and iNO alone vs. iNO/O2. More patients on the combination were acute responders compared with O2 or iNO alone (26% vs. 14%, P = 0.019, and 27% vs. 24%, P = 0.602, respectively). Changes in PVR index and mean pulmonary arterial pressure vs. baseline were greater with iNO/O2 vs. either O2 or iNO alone (P < 0.001). Survival at 1-year follow-up included (1) 90.9% of acute responders to the combination, compared with 77.8% of nonresponders to the combination, and (2) 85.7% of acute responders to O2 alone, compared with 80.6% of nonresponders to O2. Key conclusions are as follows. In children with PH and increased PVR, more acute responders were identified with the iNO/O2 combination vs. O2 alone. While there was no significant difference in acute responder rate with iNO alone vs. iNO/O2, the combination improved pulmonary hemodynamics acutely better than iNO alone. One-year survival data show similar rates between the iNO/O2 and the O2 alone groups; however, the combination may be more effective than O2 alone in discriminating survivors versus nonsurvivors at long-term follow-up.
Literature
1.
go back to reference Atz AM, Adatia I, Lock JE, Wessel DL (1999) Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33:813–819CrossRefPubMed Atz AM, Adatia I, Lock JE, Wessel DL (1999) Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33:813–819CrossRefPubMed
2.
go back to reference Badesch DB, Champion HC, Gomez-Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66CrossRefPubMed Badesch DB, Champion HC, Gomez-Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66CrossRefPubMed
3.
go back to reference Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 106(12; Suppl 1):I76–I81PubMed Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, Kaine SF, Ivy DD, Webber SA, Rothman A, Ross RD, Aggarwal S, Takahashi M, Waldman JD (2002) Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP Test Study Group. Circulation 106(12; Suppl 1):I76–I81PubMed
4.
go back to reference Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78–S84CrossRefPubMed Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54:S78–S84CrossRefPubMed
5.
go back to reference Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197–1208PubMed Barst RJ, Maislin G, Fishman AP (1999) Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99:1197–1208PubMed
6.
go back to reference Barst RJ (1986) Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. Chest 89:497–503CrossRefPubMed Barst RJ (1986) Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension. Chest 89:497–503CrossRefPubMed
7.
go back to reference Bennett D, Marcus R, Stokes M (2005) Incidents and complications during pediatric cardiac catheterization. Paediatr Anaesth 15:1083–1088PubMed Bennett D, Marcus R, Stokes M (2005) Incidents and complications during pediatric cardiac catheterization. Paediatr Anaesth 15:1083–1088PubMed
8.
go back to reference Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ (2001) Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 119:128–136CrossRefPubMed Cockrill BA, Kacmarek RM, Fifer MA, Bigatello LM, Ginns LC, Zapol WM, Semigran MJ (2001) Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 119:128–136CrossRefPubMed
9.
go back to reference Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Subirana Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493–2537CrossRefPubMed Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Subirana Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493–2537CrossRefPubMed
10.
go back to reference Houde C, Bohn DJ, Freedom RM, Rabinovitch M (1993) Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 70:461–468CrossRefPubMed Houde C, Bohn DJ, Freedom RM, Rabinovitch M (1993) Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 70:461–468CrossRefPubMed
11.
go back to reference Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A, Waagstein F, Lundin S (1994) Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13:366–375PubMed Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A, Waagstein F, Lundin S (1994) Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13:366–375PubMed
12.
go back to reference Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM (2000) Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 36:2204–2211CrossRefPubMed Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM (2000) Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 36:2204–2211CrossRefPubMed
13.
go back to reference Marshall HW, Swan HJ, Burchell HB, Wood EH (1961) Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 23:241–252PubMed Marshall HW, Swan HJ, Burchell HB, Wood EH (1961) Effect of breathing oxygen on pulmonary artery pressure and pulmonary vascular resistance in patients with ventricular septal defect. Circulation 23:241–252PubMed
14.
go back to reference McLaughlin VM, Archer SA, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA (2009) ACCF/AHA clinical expert consensus document on pulmonary hypertension. Circulation 119:2250–2294CrossRefPubMed McLaughlin VM, Archer SA, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, Moliterno DJ, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ, ACCF/AHA (2009) ACCF/AHA clinical expert consensus document on pulmonary hypertension. Circulation 119:2250–2294CrossRefPubMed
15.
go back to reference Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodriguez-Roisin R, Barbera JA (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225–234CrossRefPubMed Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, Rodriguez-Roisin R, Barbera JA (2004) Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98:225–234CrossRefPubMed
16.
go back to reference Pagano D, Townend JN, Horton R, Smith C, Clutton-Brock T, Bonser RS (1996) A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10:1120–1126CrossRefPubMed Pagano D, Townend JN, Horton R, Smith C, Clutton-Brock T, Bonser RS (1996) A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10:1120–1126CrossRefPubMed
17.
go back to reference Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173–1174CrossRefPubMed Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J (1991) Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338:1173–1174CrossRefPubMed
18.
go back to reference Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81PubMedCrossRef Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81PubMedCrossRef
19.
go back to reference Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM (1993) Inhaled nitric oxide in congenital heart disease. Circulation 87:447–453PubMed Roberts JD Jr, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM (1993) Inhaled nitric oxide in congenital heart disease. Circulation 87:447–453PubMed
20.
go back to reference Rubin LJ (2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl 1):7S–10SCrossRefPubMed Rubin LJ (2004) Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(Suppl 1):7S–10SCrossRefPubMed
21.
go back to reference Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151(2; Pt 1):384–389PubMed Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151(2; Pt 1):384–389PubMed
22.
go back to reference Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265–270CrossRefPubMed Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, Herve P, Simonneau G (1998) Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12:265–270CrossRefPubMed
23.
go back to reference Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111CrossRefPubMed Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111CrossRefPubMed
24.
go back to reference Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR (2007) Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 98:657–661CrossRefPubMed Taylor CJ, Derrick G, McEwan A, Haworth SG, Sury MR (2007) Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 98:657–661CrossRefPubMed
25.
go back to reference Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660–665CrossRefPubMed Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ (2004) Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 110:660–665CrossRefPubMed
Metadata
Title
Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension
Authors
Robyn J. Barst
Gabriella Agnoletti
Alain Fraisse
James Baldassarre
David L. Wessel
For the NO Diagnostic Study Group
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Pediatric Cardiology / Issue 5/2010
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-010-9645-5

Other articles of this Issue 5/2010

Pediatric Cardiology 5/2010 Go to the issue

Images in Pediatric Cardiology

Mycotic Aneurysm of the Left Ventricle